Mid-cycle changes in treatment-induced immune profile following Pom therapy. (A-C) Phenotypic and numeric changes in immune cells. (A) Changes in T, NK, B, and monocytes at baseline and 1 week after therapy. (B) Changes in the expression of NKG2D, CD16, and CD56 on NK cells at baseline and after 1 week of therapy. (C) Fold change (compared with baseline) in T cells (i) and NK cells (ii) at 1 week after initiation of therapy in patients with a 28/28-day schedule (cohort 1) or a 21/28-day schedule (cohort 2) at 7 days following initiation of therapy in cycle 1 (Pom alone) or with dexamethasone (cycle 2). (D-G) Changes in functional properties of T and NK cells. (D) Changes in cytokine profile of CD4⁺ or CD8⁺ T cells. Intracellular cytokine production by CD4/CD8⁺ T cells was analyzed by flow cytometry at baseline vs 7 days after initiation of therapy. (E) Changes in cytokine profile of NK cells. Intracellular cytokine production by NK cells was analyzed by flow cytometry at baseline vs 7 days after initiation of therapy. (F) Changes in cytolysis proteins in T and NK cells. Expression of granzymeB and perforin by NK and CD8⁺ T cells was analyzed by flow cytometry at baseline vs 7 days after initiation of therapy. (G) Changes in polyfunctional T cells. Intracellular cytokine production by CD4/CD8⁺ T cells was analyzed by flow cytometry at baseline vs 7 days after initiation of therapy. (H) Changes in CD25^hi FOXP3^hi Tregs. Changes in circulating CD25hiFOXP3hi Tregs following Pom therapy were analyzed by flow cytometry. (Left) Representative FACS plot. (Center) Summary of changes before and after therapy. (Right) Comparison of changes following cycles 1 and 2. (I) Changes in coinhibitory receptors. Changes in the expression of BTLA, PD1, and Tim3 on CD4/CD8⁺ T or NK cells at baseline and after 1 week of therapy.